{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:24:18Z","timestamp":1791246258164,"version":"4.1.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004167","name":"Medicines for Malaria Venture","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004167","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Parasitology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.pt.2023.01.010","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T23:10:23Z","timestamp":1676848223000},"page":"260-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7156-5725","authenticated-orcid":false,"given":"Srinivasa P.S.","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7461-9303","authenticated-orcid":false,"given":"Ujjini H.","family":"Manjunatha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-9703","authenticated-orcid":false,"given":"Sebastian","family":"Mikolajczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8221-6785","authenticated-orcid":false,"given":"Paul G.","family":"Ashigbie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8520-5683","authenticated-orcid":false,"given":"Thierry T.","family":"Diagana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pt.2023.01.010_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/bs.apar.2018.03.002","article-title":"Human parasitology and parasitic diseases: heading towards 2050","volume":"100","author":"Hotez","year":"2018","journal-title":"Adv. Parasitol."},{"key":"10.1016\/j.pt.2023.01.010_bb0010","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3390\/tropicalmed4010044","article-title":"The global burden of disease of zoonotic parasitic diseases: top 5 contenders for priority consideration","volume":"4","author":"Pisarski","year":"2019","journal-title":"Trop. Med. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0015","series-title":"World Malaria Report","author":"WHO","year":"2022"},{"key":"10.1016\/j.pt.2023.01.010_bb0020","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.gheart.2015.06.001","article-title":"The burden of Chagas disease: estimates and challenges","volume":"10","author":"Stanaway","year":"2015","journal-title":"Glob. Heart"},{"key":"10.1016\/j.pt.2023.01.010_bb0025","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.jaad.2020.08.043","article-title":"The global, regional, and national burden of leishmaniasis: an ecologic analysis from the global burden of disease study 1990\u20132017","volume":"84","author":"Scheufele","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.pt.2023.01.010_bb0030","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1021\/acsinfecdis.8b00298","article-title":"Drug discovery for kinetoplastid diseases: future directions","volume":"5","author":"Rao","year":"2019","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004729","article-title":"The burden of Cryptosporidium diarrheal disease among children < 24 months of age in moderate\/high mortality regions of sub-Saharan Africa and south Asia, utilizing data from the global enteric multicenter study (gems)","volume":"10","author":"Sow","year":"2016","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40249-018-0444-1","article-title":"Innovation in neglected tropical disease drug discovery and development","volume":"7","author":"Weng","year":"2018","journal-title":"Infect. Dis. Poverty"},{"key":"10.1016\/j.pt.2023.01.010_bb0045","series-title":"Ending the Neglect to Attain the Sustainable Development Goals: a Road Map for Neglected Tropical Diseases 2021\u20132030","author":"WHO","year":"2020"},{"key":"10.1016\/j.pt.2023.01.010_bb0050","first-page":"61","article-title":"Development and introduction of fexinidazole into the global human african trypanosomiasis program","volume":"106","author":"Valverde Mordt","year":"2022","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.010_bb0055","unstructured":"Keeping the promise: product development partnerships\u2019 role in the new age of health research and product development. Medicines for Malaria Venture. https:\/\/www.mmv.org\/sites\/default\/files\/uploads\/docs\/publications\/KeepingThePromise-Report_2021.pdf"},{"key":"10.1016\/j.pt.2023.01.010_bb0060","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/nrd4001-c1","article-title":"Drug discovery for the developing world: progress at the novartis institute for tropical diseases","volume":"14","author":"Jones","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2023.01.010_bb0065","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1056\/NEJMoa1602250","article-title":"Antimalarial activity of KAF156 in falciparum and vivax malaria","volume":"375","author":"White","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2023.01.010_bb0070","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa1315860","article-title":"Spiroindolone KAE609 for falciparum and vivax malaria","volume":"371","author":"White","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2023.01.010_bb0075","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1021\/acs.jmedchem.1c01995","article-title":"Discovery and preclinical pharmacology of INE963, a potent and fast-acting blood-stage antimalarial with a high barrier to resistance and potential for single-dose cures in uncomplicated malaria","volume":"65","author":"Taft","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2023.01.010_bb0080","doi-asserted-by":"crossref","first-page":"10773","DOI":"10.1021\/acs.jmedchem.0c00499","article-title":"Discovery and characterization of clinical candidate LXE408 as a kinetoplastid-selective proteasome inhibitor for the treatment of leishmaniases","volume":"63","author":"Nagle","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2023.01.010_bb0085","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.pt.2019.05.004","article-title":"Next-generation phenotypic screening in early drug discovery for infectious diseases","volume":"35","author":"Aulner","year":"2019","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2023.01.010_bb0090","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrd3480","article-title":"How were new medicines discovered?","volume":"10","author":"Swinney","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2023.01.010_bb0095","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1021\/acs.oprd.9b00140","article-title":"The evolution of high-throughput experimentation in pharmaceutical development and perspectives on the future","volume":"23","author":"Mennen","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.pt.2023.01.010_bb0100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.pt.2023.01.010_bb0105","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1126\/science.1193225","article-title":"Spiroindolones, a potent compound class for the treatment of malaria","volume":"329","author":"Rottmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.pt.2023.01.010_bb0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/nature19339","article-title":"Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness","volume":"537","author":"Khare","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.pt.2023.01.010_bb0115","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.pt.2021.01.009","article-title":"MalDA, accelerating malaria drug discovery","volume":"37","author":"Yang","year":"2021","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2023.01.010_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147215","article-title":"When quality beats quantity: decision theory, drug discovery, and the reproducibility crisis","volume":"11","author":"Scannell","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2023.01.010_bb0125","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1021\/acs.jcim.9b01155","article-title":"Biased diversity for effective virtual screening","volume":"60","author":"Martin","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.pt.2023.01.010_bb0130","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.01275","article-title":"QSAR-based virtual screening: advances and applications in drug discovery","volume":"9","author":"Neves","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pt.2023.01.010_bb0135","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1021\/acs.jcim.9b00375","article-title":"All-assay-max2 pQSAR: activity predictions as accurate as four-concentration IC50s for 8558 Novartis assays","volume":"59","author":"Martin","year":"2019","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.pt.2023.01.010_bb0140","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1021\/ci1005004","article-title":"Profile-QSAR: a novel meta-QSAR method that combines activities across the kinase family to accurately predict affinity, selectivity, and cellular activity","volume":"51","author":"Martin","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.pt.2023.01.010_bb0145","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.chom.2012.04.015","article-title":"Selective and specific inhibition of the Plasmodium falciparum lysyl-tRNA synthetase by the fungal secondary metabolite cladosporin","volume":"11","author":"Hoepfner","year":"2012","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pt.2023.01.010_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature12782","article-title":"Targeting Plasmodium PI(4)K to eliminate malaria","volume":"504","author":"McNamara","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.pt.2023.01.010_bb0155","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1073\/pnas.1820175116","article-title":"Preclinical candidate for the treatment of visceral leishmaniasis that acts through proteasome inhibition","volume":"116","author":"Wyllie","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2023.01.010_bb0160","doi-asserted-by":"crossref","first-page":"5060","DOI":"10.1128\/AAC.02727-13","article-title":"KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission","volume":"58","author":"Kuhen","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2023.01.010_bb0165","doi-asserted-by":"crossref","first-page":"16166","DOI":"10.1038\/nmicrobiol.2016.166","article-title":"UDP-galactose and acetyl-CoA transporters as Plasmodium multidrug resistance genes","volume":"1","author":"Lim","year":"2016","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.pt.2023.01.010_bb0170","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1126\/science.1260867","article-title":"K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates","volume":"347","author":"Straimer","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pt.2023.01.010_bb0175","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/s41564-020-0745-6","article-title":"Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors","volume":"5","author":"Saldivia","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.pt.2023.01.010_bb0180","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nature10771","article-title":"High-throughput decoding of antitrypanosomal drug efficacy and resistance","volume":"482","author":"Alsford","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.pt.2023.01.010_bb0185","doi-asserted-by":"crossref","first-page":"9616","DOI":"10.1073\/pnas.1807915115","article-title":"Clinical and veterinary trypanocidal benzoxaboroles target CPSF3","volume":"115","author":"Wall","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2023.01.010_bb0190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.chembiol.2012.01.002","article-title":"Mass spectrometry-based proteomics in preclinical drug discovery","volume":"19","author":"Schirle","year":"2012","journal-title":"Chem. Biol."},{"key":"10.1016\/j.pt.2023.01.010_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/1475-2875-13-S1-P38","article-title":"Identification of Plasmodium PI4 kinase as target of MMV390048 by chemoproteomics","volume":"13","author":"Ghidelli-Disse","year":"2014","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2023.01.010_bb0200","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41586-018-0356-z","article-title":"Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis","volume":"560","author":"Wyllie","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pt.2023.01.010_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115174","article-title":"Mass spectrometry-based cellular thermal shift assay (CETSA\u00ae) for target deconvolution in phenotypic drug discovery","volume":"28","author":"Friman","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.pt.2023.01.010_bb0210","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/2472555220927692","article-title":"Functional genomics for target identification","volume":"25","author":"Gianni","year":"2020","journal-title":"Slas Discov. Adv. Sci. Drug Discov."},{"key":"10.1016\/j.pt.2023.01.010_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau3174","article-title":"Identifying purine nucleoside phosphorylase as the target of quinine using cellular thermal shift assay","volume":"11","author":"Dziekan","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2023.01.010_bb0220","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature22337","article-title":"A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis","volume":"546","author":"Manjunatha","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.pt.2023.01.010_bb0225","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ijpara.2020.01.006","article-title":"Bumped kinase inhibitors as therapy for apicomplexan parasitic diseases: lessons learned","volume":"50","author":"Choi","year":"2020","journal-title":"Int. J. Parasitol."},{"key":"10.1016\/j.pt.2023.01.010_bb0230","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1073\/pnas.1814685116","article-title":"Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis","volume":"116","author":"Baragana","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2023.01.010_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba8412","article-title":"Bicyclic azetidines kill the diarrheal pathogen Cryptosporidium in mice by inhibiting parasite phenylalanyl-tRNA synthetase","volume":"12","author":"Vinayak","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2023.01.010_bb0240","doi-asserted-by":"crossref","first-page":"16159","DOI":"10.1021\/acs.jmedchem.1c01437","article-title":"DNDI-6148: a novel benzoxaborole preclinical candidate for the treatment of visceral leishmaniasis","volume":"64","author":"Mowbray","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.pt.2023.01.010_bb0245","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1089\/adt.2017.796","article-title":"How phenotypic screening influenced drug discovery: lessons from five years of practice","volume":"15","author":"Haasen","year":"2017","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.pt.2023.01.010_bb0250","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1186\/1475-2875-12-424","article-title":"Fast in vitro methods to determine the speed of action and the stage-specificity of anti-malarials in Plasmodium falciparum","volume":"12","author":"Le Manach","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2023.01.010_bb0255","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1475-2875-12-187","article-title":"Designing the next generation of medicines for malaria control and eradication","volume":"12","author":"Burrows","year":"2013","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2023.01.010_bb0260","doi-asserted-by":"crossref","first-page":"14025","DOI":"10.1038\/s41598-020-70860-y","article-title":"Rapid and quantitative antimalarial drug efficacy testing via the magneto-optical detection of hemozoin","volume":"10","author":"Moln\u00e1r","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2023.01.010_bb0265","article-title":"A phenotypic screen for the liver stages of plasmodium vivax","volume":"11","author":"Maher","year":"2021","journal-title":"Bio Protoc."},{"key":"10.1016\/j.pt.2023.01.010_bb0270","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12936-020-03291-9","article-title":"Assays for quantification of male and female gametocytes in human blood by qRT-PCR in the absence of pure sex-specific gametocyte standards","volume":"19","author":"Wang","year":"2020","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2023.01.010_bb0275","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.molbiopara.2011.11.003","article-title":"A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels","volume":"181","author":"Bahamontes-Rosa","year":"2012","journal-title":"Mol. Biochem. Parasitol."},{"key":"10.1016\/j.pt.2023.01.010_bb0280","doi-asserted-by":"crossref","first-page":"e0006612","DOI":"10.1371\/journal.pntd.0006612","article-title":"Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas' disease drug discovery","volume":"12","author":"MacLean","year":"2018","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0285","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001151","article-title":"SCYX-7158, an orally-active benzoxaborole for the treatment of stage 2 human african trypanosomiasis","volume":"5","author":"Jacobs","year":"2011","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0290","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1021\/acsinfecdis.7b00247","article-title":"Development of a cytopathic effect-based phenotypic screening assay against Cryptosporidium","volume":"4","author":"Chao","year":"2018","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0295","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1128\/AAC.02460-12","article-title":"Drug repurposing screen reveals FDA-approved inhibitors of human hmg-coa reductase and isoprenoid synthesis that block Cryptosporidium parvum growth","volume":"57","author":"Bessoff","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2023.01.010_bb0300","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.coisb.2018.05.004","article-title":"Machine learning and image-based profiling in drug discovery","volume":"10","author":"Scheeder","year":"2018","journal-title":"Curr. Opin. Syst. Biol."},{"key":"10.1016\/j.pt.2023.01.010_bb0305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ijpddr.2015.10.001","article-title":"Development and application of a sensitive, phenotypic, high-throughput image-based assay to identify compound activity against Trypanosoma cruzi amastigotes","volume":"5","author":"Sykes","year":"2015","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2023.01.010_bb0310","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba9338","article-title":"A machine learning approach to define antimalarial drug action from heterogeneous cell-based screens","volume":"6","author":"Ashdown","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.pt.2023.01.010_bb0315","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.chom.2018.01.002","article-title":"In vitro culture, drug sensitivity, and transcriptome of Plasmodium vivax hypnozoites","volume":"23","author":"Gural","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.pt.2023.01.010_bb0320","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.34039","article-title":"Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure","volume":"7","author":"Sanchez-Valdez","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.pt.2023.01.010_bb0325","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2217\/fmb.12.27","article-title":"Development of humanized mouse models to study human malaria parasite infection","volume":"7","author":"Vaughan","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.pt.2023.01.010_bb0330","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.omtm.2022.07.016","article-title":"Plasmodium vivax latent liver infection is characterized by persistent hypnozoites, hypnozoite-derived schizonts, and time-dependent efficacy of primaquine","volume":"26","author":"Flannery","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.pt.2023.01.010_bb0335","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fmicb.2015.00145","article-title":"No more monkeying around: primate malaria model systems are key to understanding Plasmodium vivax liver-stage biology, hypnozoites, and relapses","volume":"6","author":"Joyner","year":"2015","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.pt.2023.01.010_bb0340","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/978-1-4939-9148-8_11","article-title":"Exploiting genetically modified dual-reporter strains to monitor experimental Trypanosoma cruzi infections and host-parasite interactions","volume":"1955","author":"Taylor","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.pt.2023.01.010_bb0345","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/978-1-4939-9940-8_7","article-title":"In vivo bioluminescent monitoring of parasites in BALB\/c mouse models of cutaneous leishmaniasis drug discovery","volume":"2081","author":"Caridha","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.pt.2023.01.010_bb0350","doi-asserted-by":"crossref","first-page":"4689","DOI":"10.1038\/s41598-020-61662-3","article-title":"Establishment, optimisation and quantitation of a bioluminescent murine infection model of visceral leishmaniasis for systematic vaccine screening","volume":"10","author":"Ong","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pt.2023.01.010_bb0355","doi-asserted-by":"crossref","first-page":"e2571","DOI":"10.1371\/journal.pntd.0002571","article-title":"Highly sensitive in vivo imaging of Trypanosoma brucei expressing \"red-shifted\" luciferase","volume":"7","author":"McLatchie","year":"2013","journal-title":"PLoS Negl. Trop. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0360","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-pharmtox-010715-103429","article-title":"Model-informed drug development for malaria therapeutics","volume":"58","author":"Andrews","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.pt.2023.01.010_bb0365","series-title":"Third Symposium on Innovative Therapeutics for Cryptosporidium. Program for Appropriate Techonology in Health","article-title":"The role of gastrointestinal exposure for treating cryptosporidium infection and its implications for clinical development","author":"Manjunatha","year":"2021"},{"key":"10.1016\/j.pt.2023.01.010_bb0370","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/acsinfecdis.9b00371","article-title":"Setting our sights on infectious diseases","volume":"6","author":"De Rycker","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0375","doi-asserted-by":"crossref","first-page":"eaav1636","DOI":"10.1126\/scitranslmed.aav1636","article-title":"In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model","volume":"11","author":"Mandt","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.pt.2023.01.010_bb0380","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/cid\/ciab716","article-title":"Efficacy of cipargamin (KAE609) in a randomized, phase ii dose-escalation study in adults in sub-Saharan Africa with uncomplicated Plasmodium falciparum malaria","volume":"74","author":"Schmitt","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0385","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas' disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pt.2023.01.010_bb0390","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpddr.2016.08.003","article-title":"Assessing anti-T. cruzi candidates in vitro for sterile cidality","volume":"6","author":"Cal","year":"2016","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"10.1016\/j.pt.2023.01.010_bb0395","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1128\/AAC.00520-15","article-title":"Limited ability of posaconazole to cure both acute and chronic Trypanosoma cruzi infections revealed by highly sensitive in vivo imaging","volume":"59","author":"Francisco","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2023.01.010_bb0400","article-title":"Controlled human malaria infection: applications, advances, and challenges","volume":"86","author":"Stanisic","year":"2017","journal-title":"Infect. Immun."},{"key":"10.1016\/j.pt.2023.01.010_bb0405","doi-asserted-by":"crossref","first-page":"528","DOI":"10.4269\/ajtmh.2009.80.528","article-title":"Phase I\/II evaluation of the prophylactic antimalarial activity of pafuramidine in healthy volunteers challenged with Plasmodium falciparum sporozoites","volume":"80","author":"Nyunt","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.010_bb0410","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1021\/acsinfecdis.1c00057","article-title":"Opportunities and challenges in developing a Cryptosporidium controlled human infection model for testing antiparasitic agents","volume":"7","author":"Jumani","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0415","doi-asserted-by":"crossref","first-page":"e2407","DOI":"10.1093\/cid\/ciaa952","article-title":"Safety, pharmacokinetics, and causal prophylactic efficacy of KAF156 in a Plasmodium falciparum human infection study","volume":"73","author":"Kublin","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.pt.2023.01.010_bb0420","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01940-16","article-title":"Estimation of the in vivo mic of cipargamin in uncomplicated Plasmodium falciparum malaria","volume":"61","author":"Hien","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2023.01.010_bb0425","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01423-20","article-title":"Defining the antimalarial activity of cipargamin in healthy volunteers experimentally infected with blood-stage Plasmodium falciparum","volume":"65","author":"McCarthy","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.pt.2023.01.010_bb0430","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pt.2016.11.001","article-title":"Plasmodium vivax controlled human malaria infection \u2013 progress and prospects","volume":"33","author":"Payne","year":"2017","journal-title":"Trends Parasitol."},{"key":"10.1016\/j.pt.2023.01.010_bb0435","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bioe.12736","article-title":"What risks should be permissible in controlled human infection model studies?","volume":"34","author":"Binik","year":"2020","journal-title":"Bioethics"},{"key":"10.1016\/j.pt.2023.01.010_bb0440","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4269\/ajtmh.19-0846","article-title":"Liver enzyme elevations in Plasmodium falciparum volunteer infection studies: findings and recommendations","volume":"103","author":"Chughlay","year":"2020","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.pt.2023.01.010_bb0445","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1186\/s12936-021-04009-1","article-title":"Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa","volume":"20","author":"Ndayisaba","year":"2021","journal-title":"Malar. J."},{"key":"10.1016\/j.pt.2023.01.010_bb0450","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018162","article-title":"Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery","volume":"6","author":"Dembele","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.pt.2023.01.010_bb0455","doi-asserted-by":"crossref","DOI":"10.1590\/0074-02760200501","article-title":"The translational challenge in Chagas disease drug development","volume":"117","author":"Kratz","year":"2022","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.pt.2023.01.010_bb0460","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.4155\/bio-2021-0120","article-title":"Lessons learned from the COVID-19 pandemic and its impact on bioanalysis and drug development","volume":"13","author":"Wickremsinhe","year":"2021","journal-title":"Bioanalysis"},{"key":"10.1016\/j.pt.2023.01.010_bb0465","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17460441.2021.1854221","article-title":"Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges","volume":"16","author":"Aghila Rani","year":"2021","journal-title":"Expert. Opin. Drug Discov."},{"key":"10.1016\/j.pt.2023.01.010_bb0470","doi-asserted-by":"crossref","first-page":"e5455","DOI":"10.1073\/pnas.1414221111","article-title":"(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium","volume":"111","author":"Jim\u00e9nez-D\u00edaz","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pt.2023.01.010_bb0475","doi-asserted-by":"crossref","first-page":"14574","DOI":"10.1038\/ncomms14574","article-title":"A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue","volume":"8","author":"Sonoiki","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2023.01.010_bb0480","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14451","article-title":"A novel multiple-stage antimalarial agent that inhibits protein synthesis","volume":"522","author":"Baraga\u00f1a","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pt.2023.01.010_bb0485","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005058","article-title":"Utilizing chemical genomics to identify cytochrome b as a novel drug target for Chagas disease","volume":"11","author":"Khare","year":"2015","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.pt.2023.01.010_bb0490","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1002\/cbic.201500472","article-title":"Gift from nature: cyclomarin\u202fa kills mycobacteria and malaria parasites by distinct modes of action","volume":"16","author":"B\u00fcrstner","year":"2015","journal-title":"ChemBioChem"},{"key":"10.1016\/j.pt.2023.01.010_bb0495","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1038\/s41467-019-10687-y","article-title":"Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis","volume":"10","author":"Lunde","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pt.2023.01.010_bb0500","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02061-18","article-title":"Optimization of methionyl tRNA-synthetase inhibitors for treatment of Cryptosporidium infection","volume":"63","author":"Buckner","year":"2019","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Trends in Parasitology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492223000144?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471492223000144?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:40:39Z","timestamp":1761464439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471492223000144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":100,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S1471492223000144"],"URL":"https:\/\/doi.org\/10.1016\/j.pt.2023.01.010","relation":{},"ISSN":["1471-4922"],"issn-type":[{"value":"1471-4922","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug discovery for parasitic diseases: powered by technology, enabled by pharmacology, informed by clinical science","name":"articletitle","label":"Article Title"},{"value":"Trends in Parasitology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pt.2023.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}